Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vertex Pharmaceuticals (VRTX) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (725)	10/5/2005 10:57:39 AM
From: tuck	Read Replies (1) \| Respond to of 1169

[VX-680: "Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases"] pnas.org Full text freebie from PNAS. The authors are from Ambit, an interesting local (San Diego) private company that really knows its kinases. Cheers, Tuck

To: Miljenko Zuanic who wrote (725)	10/5/2005 1:05:44 PM
From: tuck	Read Replies (1) \| Respond to of 1169

>>Any info on SCIO/J&J progress?<< Hard to find the info, but progress seems slow, considering these compounds were in play two years ago when J&J made the munch. One MDS PI/II trial recruiting: clinicaltrials.gov I'm not sure if the names of the compounds have changed. There seem to be some new preclinical candidates with the prefix SD, such as SD-282, which makes me wonder what's what. One could probably sort it out by paying for the latest review of them in Current Opinions of Investigational Drugs. Cheers, Tuck